Evidence map›Paper›PMID 29152063›Full record

ArticleOncotarget2017

Acquisition of an oncogenic fusion protein is sufficient to globally alter the landscape of miRNA expression to inhibit myogenic differentiation.

Jacob M Loupe, Patrick J Miller, Judy S Crabtree, Jovanny Zabaleta, Andrew D Hollenbach

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jacob M Loupe *Current/Present address: Center for Human Genetic Research, Massachusetts General Hospital, Richard B. Simches Research Center, Boston, MA 02114, USA.
Patrick J Miller *Current/Present address: Tulane University, New Orleans, LA 70112, USA.
Judy S CrabtreeLouisiana State University Health Sciences Center, Department of Genetics, New Orleans, LA 70112, USA.
Jovanny ZabaletaLouisiana State University Health Sciences Center, Department of Pediatrics and Stanley S. Scott Cancer Center, New Orleans, LA 70112, USA.
Andrew D HollenbachLouisiana State University Health Sciences Center, Department of Genetics, New Orleans, LA 70112, USA.
Louisiana State University Health Sciences Center New Orleans · USMassachusetts General Hospital · USTulane University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Molecular and Soc. Determinants of Obesity and Metabolic Disorders in YouthU54MD008176 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N. · 2012 to 2016
$13.7M
Mentoring Translational Researchers in LouisianaP20GM103501 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2012 to 2014
$6.3M
Training CoreP20MD004817 · NIMHD · DILLARD UNIVERSITY · PI HAGENSEE, MICHAEL · 2010 to 2014
$6.3M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
Mechanism of regulation for the oncogenic Pax3-FOXO1 in Alveolar RhabdomyosarcomaR01CA138656 · NCI · LSU HEALTH SCIENCES CENTER · PI HOLLENBACH, ANDREW DURRELL · 2009 to 2013
$1.4M
NCI NIH HHS R01 CA138656NIGMS NIH HHS P20 GM103501NIGMS NIH HHS P30 GM114732NIGMS NIH HHS U54 GM104940NIMHD NIH HHS P20 MD004817NIMHD NIH HHS U54 MD008176
6 · The paper itself

Abstract

The differentiation status of tumors is used as a prognostic indicator, with tumors comprised of less differentiated cells exhibiting higher levels of aggressiveness that correlate with a poor prognosis. Although oncogenes contribute to blocking differentiation, it is not clear how they globally alter miRNA expression during differentiation to achieve this result. The pediatric sarcoma Alveolar Rhabdomyosarcoma, which is primarily characterized by the expression of the PAX3-FOXO1 oncogenic fusion protein, consists of undifferentiated muscle cells. However, it is unclear what role PAX3-FOXO1 plays in promoting the undifferentiated state. We demonstrate that expression of PAX3-FOXO1 globally alters the expression of over 80 individual miRNA during early myogenic differentiation, resulting in three primary effects: 1) inhibition of the expression of 51 miRNA essential for promoting myogenesis, 2) promoting the aberrant expression of 43 miRNA not normally expressed during myogenesis, and 3) altering the expression pattern of 39 additional miRNA. Combined, these changes are predicted to have an overall negative effect on myogenic differentiation. This is one of the first studies describing how an oncogene globally alters miRNA expression to block differentiation and has clinical implications for the development of much needed multi-faceted tumor-specific therapeutic regimens.

Indexed as

alveolar rhabdomyosarcomamyogenesisPAX3-FOXO1

Identifiers

PMID29152063
PMCPMC5675615
OpenAlexW2741018557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.